covid vaccine (BNT162b2) they are jointly developing to be submitted for regulatory review as early as October. Subject to regulatory approval, the companies said that they currently plan to supply up to 100 million doses of coronavirus worldwide by the end of 2020 and approximately 1.3 billion doses by the end of 2021.Here are 10 updates on Pfizer covid vaccine:1) Pfizer Inc.
and BioNTech SE have also released additional data from an early-stage study.2) The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants. "Across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants," the companies said.3) The companies.